50 results about "Enoxolone" patented technology

The invention provides glycyrrhizic acid / glycyrrhetinic acid-triethanolamine composite hydrogel as well as a preparation method and application thereof, and belongs to the technical field of preparation of biological medicine carriers and composite materials. According to the invention, glycyrrhizic acid or glycyrrhetinic acid is taken as a raw material, triethanolamine is taken as a cross-linking regulating agent, and the composite hydrogel with stable mechanical properties, high drug loading efficiency and anti-inflammatory synergistic activity is prepared through a mild physical and chemical cross-linking reaction; the preparation process of the composite hydrogel does not need a toxic cross-linking agent, the reaction condition is mild, the raw materials are cheap and easy to obtain, and large-scale production can be realized; the composite hydrogel presents a multi-group ionic bond cross-linked structure, can be used as a carrier of a pH responsive drug, and has good practicability.

The application discloses application of glycyrrhetinic acid as a feed additive to improve the egg laying rate of laying hens. In the laying hen diet of the application, only glycyrrhetinic acid is added, and no chemical synthetic drugs and hormone substances are added, so that the safety of chicken and egg products is guaranteed from the source. The application fully considers the feed cost in application and feed preparation problems, selects glycyrrhetinic acid with low cost, fully plays the medicinal value of traditional Chinese medicinal materials, and the glycyrrhetinic acid is a natural plant extract, has no toxic side effects on laying hens, meanwhile, the preparation and purification method of the glycyrrhetinic acid is simple, the market price is low, and the glycyrrhetinic acid has the advantages of large-scale application.

The present invention aims to provide a scalp composition, such as a hair growth agent or hair restoration agent, comprising at least glycyrrhetinic acid or a salt thereof, polyoxyethylene hydrogenated castor oil, and ethanol, wherein the composition does not cause the precipitation of precipitates over time. [Solution] A scalp composition that does not produce precipitates and / or insoluble matter can be provided by comprising (A) glycyrrhetinic acid or a salt thereof, (B) polyoxyethylene hydrogenated castor oil, (C) ethanol, and (D) one or more selected from the group consisting of 1,3-butylene glycol and polyethylene glycol monooleate.

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The present application relates to the field of detection, and particularly relates to a hybridoma cell strain XXML-2G11A7, a preparation method and application thereof; the hybridoma cell strain XXML-2G11A7 has a preservation number of CGMCC NO: 46139, a preservation date of November 21, 2024, and a preservation unit of China General Microbiological Culture Collection Center, and a preservation unit address of No. 3, Institute of Microbiology, Chinese Academy of Sciences, 1st North Chenxi Road, Chaoyang District, Beijing; the antibody secreted by the hybridoma cell strain XXML-2G11A7 of the present application can specifically detect enoxolone, has high sensitivity and good accuracy.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

The invention relates to application of azole drugs in preparation of antifungal drugs, and belongs to the technical field of research and development of antifungal drugs. According to the application of the glycyrrhetinic acid combined with the azoles in preparation of the antifungal drugs, the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole shows a good synergistic effect or antagonistic effect on aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans, and the application of the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole in preparation of the antifungal drugs is disclosed. And a research and development direction is provided for preparing medicines for resisting aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans.

Provided are a cosurfactant-free microemulsion encapsulating glycyrrhetinic acid, a preparation method therefor, and use thereof. The cosurfactant-free microemulsion comprises carvacrol / thymol, a fatty acid, a nonionic surfactant, and water. Based on the mass percentage of the raw materials, the glycyrrhetinic acid accounts for 0.1-5%, the carvacrol / thymol accounts for 0.1-5%, the fatty acid accounts for 0.1-10%, the nonionic surfactant accounts for 1-30%, and the balance is made up to 100% with water. Carvacrol / thymol not only increases the solubility of glycyrrhetinic acid, but also promotes the transdermal absorption of glycyrrhetinic acid, and is a cosmetic composite efficacy composition having antioxidant, anti-inflammatory, and antibacterial effects.

The application discloses a kind of 18 beta-glycyrrhetinic acid ester derivatives with PPAR gamma agonistic activity and its preparation method and application, belongs to chemical pharmaceutical technical field, specifically related to a kind of 18 beta-glycyrrhetinic acid ester derivatives molecules and its application as PPAR gamma agonist in antitumor aspect.The application uses Steglich esterification reaction, with dicyclohexyl carbodiimide and 4-dimethylaminopyridine as catalyst, 18 beta-glycyrrhetinic acid is reacted with different types of carboxylic acid, and a kind of novel 18 beta-glycyrrhetinic acid ester derivative molecules are obtained by semi-synthesis;Computer simulation molecular docking and in vitro enzyme activity experiment show that this kind of molecule can be used as PPAR gamma agonist and play significant antitumor activity.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

The invention belongs to the technical field of biology and new medicine, and discloses a preparation method of acoustic resonance driven glycyrrhizic acid nano-composite responsive gel, glycyrrhizic acid is used as a drug carrying system, berberine, ursolic acid, baicalein, luteolinin, curcumin, baicalin or ginsenoside Rh2 is used as a water-insoluble natural small molecule drug, and the acoustic resonance driven glycyrrhizic acid nano-composite responsive gel is prepared. Glycyrrhizic acid is an amphiphilic compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, a hydrophobic cavity can be formed in a water environment to wrap the water-insoluble natural small molecule medicine, a glycyrrhizic acid nano-composite solution is formed, and meanwhile the solubility of the water-insoluble natural small molecule medicine such as baicalein is improved.

The invention discloses a high-efficiency targeted anti-hepatic fibrosis oral nano drug delivery system and a preparation method thereof. According to the system, a sesquiterpene lactone component, namely lettuce lactone (LC), in Xinjiang traditional liver protection medicinal material cichorium glandulosum is used as a medicine core, and although the lettuce lactone has a good anti-fibrosis effect, the lettuce lactone (LC) has the problems of poor water solubility, high first-pass metabolism and the like. Therefore, 18 beta-glycyrrhetinic acid modified silicon-based hybrid micelles (LC-FS-G) are studied and constructed, the liver targeting property of glycyrrhetinic acid and a silicon-based cross-linked structure are utilized to enhance the stability, and drug release is responded in a glutathione (GSH) high expression environment by virtue of a disulfide bond. The particle size of the obtained micelle is uniform (27.83 nm), the encapsulation efficiency reaches 95.05%, and the drug loading rate is 10.62%. The system is slowly released in gastric juice (48h release lt); 50%), and the gt can be quickly released in a high GSH environment (36h release gt; 87%), and the liver fibrosis process can be reversed by regulating and controlling a TGF-beta / Smad pathway. According to the strategy, physicochemical and metabolic restrictions of LC are overcome, and a new way with high efficiency and low toxicity is provided for oral nano targeted therapy of hepatic fibrosis.

The application belongs to the technical field of medicine, and specifically discloses a glycyrrhetinic acid injectable hydrogel as well as a preparation method and application thereof. The preparation method of the glycyrrhetinic acid injectable hydrogel comprises the following steps: glycyrrhetinic acid and choline hydroxide are added into pure water, heated and stirred to fully react, and a mixed solution is obtained; the mixed solution is first spin-evaporated and then vacuum-dried to obtain glycyrrhetinic acid-choline; the glycyrrhetinic acid-choline is added into pure water, heated to completely dissolve and cooled at room temperature to form an injectable hydrogel. The hydrogel is used for preparing an antitumor drug in an injectable dosage form. In the application, the glycyrrhetinic acid and the choline hydroxide are self-assembled into a hydrogel with a three-dimensional network microstructure by losing one molecule of water without adding any cross-linking agent and organic solvent. The hydrogel can quickly recover to the original gel state after injection, and the problems of low drug loading, low bioavailability and difficult degradation existing in the prior art are solved.

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.

The invention discloses an intestinal barrier repairing agent based on glycyrrhizic acid derivatives and a preparation method thereof, and relates to the field of pharmaceutical preparations, the intestinal barrier repairing agent comprises a repairing unit, a regulating unit and a delivery system for controlled release; the repairing unit comprises 18 beta-glycyrrhetinic acid and glycyrrhizol; the regulating unit comprises probiotics and prebiotics; according to the intestinal barrier repairing agent based on the glycyrrhizic acid derivative and the preparation method of the intestinal barrier repairing agent, through sequential release design of firstly adjusting a microenvironment and then executing repairing, the bottlenecks of disordered component release and insufficient synergy in the prior art are overcome; the colon programmed release logic of probiotic pilot colonization and subsequent repair of licorice active ingredients is established for the first time, and the physiological healing rule of the intestinal barrier is better met; by adopting a physically mixed double-layer heterogeneous pellet structure, not only is the activity of probiotics ensured, but also the efficient delivery of insoluble drugs is realized, and the process feasibility is high.

The invention discloses a skin cell nucleus nutritional agent containing traditional Chinese medicine components and capable of improving ichthyosis and a preparation method, and relates to the technical field of preparation of skin cell nucleus nutritional agents. Comprising the following raw materials: modified vitamin A propionate, a traditional Chinese medicine extract, modified hydrogenated lecithin, squalane, beewax, stearyl alcohol, vaseline, glycerin, sodium hyaluronate, beta-glucan, propylene glycol, potassium cetyl phosphate, a preservative, allantoin, deionized water, triethanolamine and a lipid solvent. According to the invention, the modified tretinoin propionate is added, and the modified tretinoin propionate is subjected to double-grafting modification through glycyrrhetinic acid-hyaluronic acid oligosaccharide and is gently combined with a basal cell tretinoin receptor in a targeted manner, so that excessive proliferation of basal cells can be inhibited, and normal differentiation of keratinocytes can be promoted; wherein the glycyrrhetinic acid component can resist inflammation, relieve and reduce self-irritation, and the hyaluronic acid oligosaccharide can improve targeting and transdermal efficiency, avoid light / oxygen degradation and provide a core regulation effect for restoring the 28-day metabolic cycle of basal cells.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The application provides a glycyrrhetinic acid derivative, a pharmaceutical composition and application thereof, relates to the technical field of medicinal chemistry, and the main skeleton of the glycyrrhetinic acid derivative prepared by the application is glycyrrhetinic acid with a urea group; the 3th position, the 11th position, the 18th position and the 30th position of the glycyrrhetinic acid are modified, so that the glycyrrhetinic acid derivative has nanomolar level inhibitory activity on soluble epoxide hydrolase. Different urea group substituents are introduced into the 30th position on the basis of 18alpha / 18beta-glycyrrhetinic acid, and the activity difference between different substituents is small, but when different urea group substituents are connected to the 20th position of 18alpha / 18beta-glycyrrhetinic acid, the inhibitory effect of the glycyrrhetinic acid derivative on soluble epoxide hydrolase is greatly reduced. The glycyrrhetinic acid derivative prepared by the application has high inhibitory effect on soluble epoxide hydrolase, so that the inhibitory effect on inflammation can be realized by inhibiting soluble epoxide hydrolase, and the glycyrrhetinic acid derivative has good application prospect.

The present application relates to the technical field of oral care, in particular to a plant polyphenol compound based on collagen microspheres and a preparation method and application thereof.The plant polyphenol compound based on collagen microspheres comprises the following raw material components in percentage by weight: soluble collagen 0.5-6%, crosslinking agent 0.01-0.5%, notoginseng extract 0.1-3%, honeysuckle extract 0.1-3%, glycyrrhetinic acid 0.1-1%, hydroxypropyl-beta-cyclodextrin 0.1-3%, mannitol 1-8%, and the rest is an oral care acceptable auxiliary.The present application realizes the slow release and synergistic effect of plant polyphenols by forming a microsphere structure through collagen self-assembly, has good biocompatibility and significant anti-inflammatory, heat-clearing, cell adhesion and repair promoting functions, and can be stable during the storage period, mucosa resident after brushing, and responsive release in the oral environment.

The invention discloses a traditional Chinese medicine composition for treating rhinitis and a preparation method thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine raw materials and functional auxiliary materials, wherein the traditional Chinese medicine raw materials comprise the following medicinal materials in percentage by weight: 12% of biond magnolia flower, 12% of small centipeda herb, 15% of dwarf lilyturf tuber, 3% of wild chrysanthemum flower, 3% of dahurian angelica root, 3% of dandelion, 3% of manchurian wildginger, 3% of cocklebur fruit, 8% of common burreed rhizome, 8% of curcuma zedoary, 10% of red-rooted salvia root, 6% of szechuan lovage rhizome and 6% of thunberg fritillary bulb; the functional auxiliary materials comprise the following raw materials in percentage by weight: 0.4% of cellulase, 0.2% of pectinase, 1.2% of carbomer, 0.8% of poloxamer, 0.1% of glycyrrhetinic acid, 0.05% of limonene, 5.24% of chitosan-sodium alginate and 0.01% of an anti-VEGF antibody. According to the application, a nasal polyp targeting component is added, so that the dual effects of dredging orifices, resisting inflammation (rhinitis) and resisting fiber (nasal polyp) are realized; the clinical value is higher than that of single rhinitis treatment; plant cell walls are destroyed by adopting composite enzymolysis, and fat-soluble, water-soluble and volatile oil active ingredients are synchronously extracted in combination with supercritical CO2 extraction; the mucous membrane stimulation risk caused by impurities is reduced.

This invention belongs to the field of biomedical technology, specifically relating to an organic selenium composition for inhibiting tumor cells and its preparation method. The organic selenium composition comprises the following components in parts by weight: 7-12 parts selenobenzonitrile-glycyrrhizinamide, 2-5 parts trazastilbene, and 0.5-1 part selenized carrageenan. This invention utilizes the reaction of the carbonyl α,β-unsaturated olefin bond in methyl glycyrrhizinic acid with 4-mercaptobenzonitrile to introduce a benzonitrile structure to enhance targeting while retaining the core active structure of methyl glycyrrhizinic acid. Simultaneously, a selenium compound is introduced onto the carboxyl group of methyl glycyrrhizinic acid, thereby preparing selenobenzonitrile-glycyrrhizinamide. When selenobenzonitrile-glycyrrhizinamide is used in combination with trazastilbene and selenized carrageenan, the prepared organic selenium composition exhibits significant inhibitory effects on the proliferation of various tumor cells, while showing no significant toxicity to normal human liver cells (L02).

The invention discloses a 18 beta-glycyrrhetinic acid derivative containing a diene structure fragment as shown in a general formula I and a preparation method and application thereof, and belongs to the technical field of medicines, the compound can effectively degrade HDAC3, and further mechanism studies (including Western Blot and quantitative proteomics) prove that a representative compound can effectively degrade the HDAC3 by inducing the degradation of the HDAC3 through specificity. Further, an NLRP3 inflammasome pathway is inhibited, and finally, maturation and secretion of downstream inflammatory factors IL-1beta and caspase-1 are blocked, so that a remarkable anti-inflammatory effect is achieved. A mouse acute shock and colitis model further verifies the excellent anti-inflammatory activity of the compound in vivo. The invention not only provides a novel HDAC3 degradation agent with good activity, but also lays a solid material and theoretical foundation for deep development of anti-inflammatory drugs based on the 18 beta-glycyrrhetinic acid structure.

The present invention relates to compounds obtainable by the chemical modification of glycyrrhetinic acid, pharmaceutical preparations and uses thereof, and a method for preparing same. The method comprises chemically modifying glycyrrhetinic acid by transforming hydroxyl at position 3 into an N-arylsulphonylhydrazone and the subsequent reactions thereof. The method comprises obtaining arylated and heteroarylated glycyrrhetinic acid derivatives at position 3. The method further comprises obtaining glycyrrhetinic acid-derived spiropyrazoles. The method further comprises obtaining fused pyrazoles by expanding the A ring of the spiropyrazoles. The method further comprises obtaining tetracyclic glycyrrhetinic acid derivatives by opening the A ring of the spiropyrazoles. The obtainable compounds exhibit pharmacological activity against various diseases. The invention is suitable for use in the chemical and pharmaceutical industry, with an interest in the therapeutic activity of glycyrrhetinic acid and the derivatives thereof.

To provide a composition that inhibits neutrophil collagenase activity.SOLUTION: An oral composition contains β-glycyrrhetinic acid and zinc gluconate. A content of the zinc gluconate is 0.06-7.5 pts.mass relative to 1 pt.mass of the β-glycyrrhetinic acid in the oral composition.SELECTED DRAWING: None

The application provides a complex of glycyrrhetinic acid and a cyclodextrin-metal organic framework, specifically, the complex takes the cyclodextrin-metal organic framework as a carrier, and the glycyrrhetinic acid enters the cavity of the cyclodextrin-metal organic framework to form the complex. The complex can greatly improve the solubility of the glycyrrhetinic acid, has a biphasic release characteristic, can improve the biological activity of the glycyrrhetinic acid, reduces the administration frequency, and increases the medication compliance. In addition, the complex can effectively deliver the glycyrrhetinic acid to the lung for treating lung diseases, provides a good intermediate for inhalation preparation and oral administration of the glycyrrhetinic acid, and has a simple and safe preparation process.

The application relates to the application of azole drugs in the preparation of antifungal drugs and belongs to the technical field of antifungal drug research and development. The application of glycyrrhetic acid combined with azole drugs in the preparation of antifungal drugs discloses that glycyrrhetic acid combined with itraconazole, voriconazole and posaconazole shows good synergistic effect or antagonistic effect on aspergillus, exophiala dermatiditis, candida and new cryptococcus, and provides a research and development direction for preparing drugs for resisting aspergillus, exophiala dermatiditis, candida and new cryptococcus.

The invention relates to the technical field of cosmetics, in particular to a composite ceramide liposome with moisturizing, repairing and soothing effects as well as a preparation method and application of the composite ceramide liposome. The composite ceramide liposome is prepared from the following components: ceramide NP, ceramide NS / ceramide NG, ceramide AP, hyaluronic acid, glycyrrhetinic acid, kaempferol, an emulsifier, a co-emulsifier, a stabilizer and the balance of water. The composite ceramide liposome prepared by compounding the moisturizing, repairing and soothing functional components with the hyaluronic acid, the glycyrrhetinic acid, the kaempferol and other components has the effects of excellent stability, inflammation resistance, moisturizing, bacteriostasis, oxidation resistance and ABTS free radical removal, can effectively promote the proliferation of HaCaT cells, and also has the effects of repairing and soothing the skin.